Advancing Precision Therapeutics in Older Adults: A Scoping Review of Pharmacogenomic Service Models
Advancing Precision Therapeutics in Older Adults: Scoping Review von Pharmacogenomic Service Models
Clinical Pharmacology & Therapeutics · 10.11.2026
DOI: 10.1002/cpt.70547 ↗Auf einen Blick
Die Scoping-Review beschreibt 11 pharmakogenomische Services bei Erwachsenen ab 65 Jahren. Die meisten waren in Programme zum Medikationsmanagement eingebettet.
Fragestellung
Welche pharmakogenomischen Testservices wurden bei Erwachsenen ab 65 Jahren umgesetzt, und welche Merkmale unterstützen die Nutzung genetischer Informationen für Therapieentscheidungen?
Methode
Scoping-Review; 5 Datenbanken von Beginn bis Mai 2026; nur Studien, in denen Testergebnisse Verordnungsentscheidungen informierten; Auswertung nach PRISMA.
Ergebnisse
Identifiziert wurden 11 pharmakogenomische Services in unterschiedlichen Settings, darunter Primärversorgung, geriatrische Ambulanzen, stationäre Altenpflege, Apotheken und Telepharmazien. Genannt wurden 7 unterstützende Designelemente.
Schlussfolgerung der Autor:innen
Die Ergebnisse liefern einen pragmatischen Rahmen für die Gestaltung pharmakogenomischer Services und benennen Prioritäten für künftige Implementierung und Evaluation.
Kernaussagen
- 11 pharmakogenomische Services in verschiedenen Versorgungssettings
- 7 Designelemente zur Unterstützung der Implementierung
- Meist eingebettet in bestehende Medikationsmanagement-Programme
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 10.11.2026. Verfasst von Eman Wehbe und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia. Die Arbeit nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Gerontologische Pflege
Abstract (Originalsprache)
Older adults remain a therapeutically understudied population despite experiencing the highest burden of polypharmacy, age‐related pharmacokinetic and pharmacodynamic variability, and medication‐related harm. Pharmacogenomic testing offers an opportunity to individualize drug therapy in this population; however, its clinical implementation is complicated by population‐specific challenges. We conducted a scoping review to describe existing pharmacogenomic testing services implemented in adults aged ≥ 65 years and to identify design features that support translation of genomic information into therapeutic decision making. Five databases were searched from inception to May 2026. Studies were included if pharmacogenomic test results were used to inform prescribing decisions. Data were extracted on pre‐implementation actions, implementation workflows and types of outcomes assessed. The review was conducted in accordance with the PRISMA guidelines. Eleven pharmacogenomic services were identified, implemented across diverse settings including primary care, geriatric clinics, residential aged care, pharmacies, and telepharmacies. Multiple design elements were deduced to support therapeutic integration of pharmacogenomic testing: (1) leveraging medication management workflows, (2) delivering pre‐implementation healthcare professional education, (3) targeting population‐relevant gene and allele panels, (4) establishing simplified organizational guidelines, (5) utilizing clinical decision support tools to identify drug‐gene and drug–drug‐gene interactions, (6) pharmacist‐led interpretation of results, and (7) iterative service evaluation. Notably, most services were embedded within broader medication management programs, positioning pharmacogenomic testing as a tool to refine, rather than replace, existing therapeutic decision making in older adults. The findings provide a pragmatic framework for designing pharmacogenomic services that advance precision therapeutics in older adults and highlight priorities for future implementation and evaluation.
Autor:innen und Institutionen
- School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
- myDNA Life, Australia Limited, South Yarra, Victoria, Australia.
- Centre for Medicine Use and Safety, Monash University, Parkville, Victoria, Australia.
- Department of Pharmacy, Westmead Hospital, Sydney, New South Wales, Australia.
- Sydney Institute for Infectious Diseases, The University of Sydney, Sydney, New South Wales, Australia.
- Department of Clinical Pharmacology and Toxicology, St Vincent's Hospital, Sydney, New South Wales, Australia.
ORCID-Profile: Eman Wehbe, Tark J Patel, Stephen Hughes, Sam Mostafa, Carl M Kirkpatrick, Sophie L Stocker
Zitieren
APA
Wehbe, E., Patel, T. J., Hughes, S., Mostafa, S., Kirkpatrick, C. M., & Stocker, S. L. (2026). Advancing Precision Therapeutics in Older Adults: A Scoping Review of Pharmacogenomic Service Models. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.70547
Vancouver
Wehbe E, Patel TJ, Hughes S, Mostafa S, Kirkpatrick CM, Stocker SL. Advancing Precision Therapeutics in Older Adults: A Scoping Review of Pharmacogenomic Service Models. Clinical Pharmacology & Therapeutics. 2026. doi:10.1002/cpt.70547
BibTeX
@article{Wehbe2026,
author = {Wehbe, Eman and Patel, Tark J and Hughes, Stephen and Mostafa, Sam and Kirkpatrick, Carl M and Stocker, Sophie L},
title = {Advancing Precision Therapeutics in Older Adults: A Scoping Review of Pharmacogenomic Service Models},
journal = {Clinical Pharmacology & Therapeutics},
year = {2026},
doi = {10.1002/cpt.70547}
}
EUVIMED